Silicogenix
Silicogenix uses AI-powered computational chemistry to design novel small-molecule drug candidates for rare cancers. Its CADDE environment enables rapid, design-driven chemistry focused on non-traditional modalities such as allosteric, linked, and bispecific molecules. The approach leverages AI, machine learning, and high-throughput in silico screening to generate thousands of high-affinity scaffolds against multiple targets in parallel. Silicogenix collaborates with research partners to advance programs toward preclinical stages, offering SaaS, licensing, and services to pharma and research teams.
Silicogenix
Silicogenix uses AI-powered computational chemistry to design novel small-molecule drug candidates for rare cancers. Its CADDE environment enables rapid, design-driven chemistry focused on non-traditional modalities such as allosteric, linked, and bispecific molecules. The approach leverages AI, machine learning, and high-throughput in silico screening to generate thousands of high-affinity scaffolds against multiple targets in parallel. Silicogenix collaborates with research partners to advance programs toward preclinical stages, offering SaaS, licensing, and services to pharma and research teams.